Oruka Therapeutics, Inc.
NASDAQ:ORKABiotechnology
+$0.46 today
- Market cap
- $6.49B
- Beta
- -0.30
- P/E (TTM)
- -33.9
- EPS (TTM)
- -$2.11
Volume 0.52M
Average 1.55M
ORKA Common Stock Issued
Cash raised by issuing new shares.
Oruka Therapeutics, Inc.NASDAQ: ORKA
Common Stock Issued · Q3 FY2026 · quarter ended Sep 2026
Common stock issued outflow grows to $126.77M
Q3 FY2026 common stock issued was $126.77M, compared with $0 a year earlier. Trailing-twelve-month common stock issued was $830.71M.
Context
- Common stock issued increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly common stock issued holds near $126.77M or moves back toward the trailing-twelve-month quarterly average of $207.68M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Common Stock Issued history
USD · from the cash flow
- Latest · FY2025
- 170.32M USD
- Year-over-year change
- -62.1%
- 5-year CAGR
- +28.4%
| Period | Period end | Common Stock Issued | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 170.32M | -62.1% |
| FY2024 | 2024-12-31 | 449.54M | — |
| FY2022 | 2022-12-31 | 0 | -100.0% |
| FY2021 | 2021-12-31 | 23.09M | -52.7% |
| FY2020 | 2020-12-31 | 48.86M | — |
Common Stock Issued vs competitors
How ORKA compares with its peers on the latest reported figures
- ORKA's LTM Sep 2026 common stock issued of $830.71M is the largest of the 10 companies compared; the peer median is $64.4M.
- Its year-over-year change of +2715.7% is the 2nd highest of 10, against a peer median of +71.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
ORKAOruka Therapeutics, Inc. | LTM Sep 2026 | $830.71M | +2715.7% | — | — |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $360.93M | +86.0% | — | 4878.8% |
| FY2025 | $142.01M | +71.3% | — | 10519.4% | |
ZURAZura Bio Limited | LTM Mar 2026 | $135.23M | +2555.3% | — | — |
| LTM Mar 2026 | $78.57M | +31216.6% | +2580.0% | — | |
| LTM Jun 2026 | $64.4M | +60.1% | — | 3382.4% | |
| LTM Mar 2026 | $58.03M | -22.6% | — | 693.6% | |
| LTM Mar 2026 | $27.99M | -72.1% | +6.4% | 12.0% | |
| LTM Jun 2026 | $8.3M | -95.7% | — | 7.9% | |
| FY2025 | $1.09M | +381.5% | +293.1% | 1707.8% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ORKA) | $64.4M | +71.3% | +293.1% | 1707.8% | |
Competitors are the stored peer set for ORKA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2020 Dec 2020 | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (9.74M) | (19.32M) | (9.93M) | (83.72M) | (105.43M) |
| Depreciation & Amortization | 93K | 91K | 114K | 27K | 83K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 |
| Change in Working Capital | 1.88M | (28K) | (1.66M) | 11.59M | (2.56M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.1M | (411K) | (783K) | 3.46M | 693K |
| Other Working Capital | 776K | 383K | (878K) | 8.13M | (3.25M) |
| Other Non-Cash Items | 43K | 497K | 561K | 14.27M | 19.7M |
| Operating Cash Flow | (7.73M) | (18.76M) | (10.91M) | (57.84M) | (88.21M) |
| Capital Expenditures | (19K) | (43K) | (2K) | (189K) | (209K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (329.94M) | (520.96M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 424.42M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (19K) | (43K) | (2K) | (330.13M) | (96.75M) |
| Debt Repayment | (408K) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 48.86M | 23.09M | 0 | 449.54M | 170.32M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 48.45M | 23.09M | 0 | 449.54M | 170.32M |
| Effect of Forex Changes | 0 | 0 | 0 | (37.43M) | 0 |
| Net Change in Cash | 40.71M | 4.29M | (10.91M) | 24.14M | (14.64M) |
| Free Cash Flow | (7.74M) | (18.81M) | (10.91M) | (58.03M) | (88.42M) |
Oruka Therapeutics, Inc.
NASDAQ:ORKA
Intrinsic Alpha fair value
Locked
Current Price
$95.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.